Net margin is calculated as Net Income divided by its Revenue. Moolec Science's Net Income for the
six
months ended in Dec. 2025 was $69.0 Mil. Moolec Science's Revenue for the
six
months ended in Dec. 2025 was $5.2 Mil. Therefore, Moolec Science's net margin for the quarter that ended in Dec. 2025 was 1,318.60%.
The historical rank and industry rank for Moolec Science's Net Margin % or its related term are showing as below:
MLEC'
s Net Margin % Range Over the Past 10 Years
Min: -33.41 Med: -7.01 Max: 9.61
Current: -2.77
MLEC's Net Margin % is ranked better than 69.8% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs MLEC: -2.77
Moolec Science (NAS:MLEC) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Moolec Science Net Margin % Related Terms
Moolec Science Net Margin % Historical Data
* Premium members only.
The historical data trend for Moolec Science's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Moolec Science's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's Net Margin % distribution charts can be found below:
* The bar in red indicates where Moolec Science's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moolec Science (MLEC) has a Net Margin % of 1,318.60% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Moolec Science and its competitors. According to the industry distribution chart, Moolec Science ranks #286 out of 947 companies in the Biotechnology industry, placing it in the top 30.2%.
Is Moolec Science's Net Margin % too high?
Moolec Science's current Net Margin % is 1,318.60%. Based on the distribution chart, Moolec Science ranks #286 out of 947 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Moolec Science has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's Net Margin % compare to RVPH and CDIO?
According to the Biotechnology industry distribution chart, Moolec Science ranks #286 out of 947 companies for Net Margin %. This puts Moolec Science in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Moolec Science and its competitors. Moolec Science's current Net Margin % is 1,318.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $7.62 — trading 91% below its estimated fair value. The current Net Margin % is 1,318.60%. Moolec Science's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Moolec Science (MLEC), the current Net Margin % is 1,318.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $7.62 is trading 91% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
Key valuation signals for MLEC:
Net Margin %: 1,318.60%
GF Value™: $84.84 vs. price of $7.62 (91% below fair value)
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
46GF Score
Get the complete analysis for MLEC
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
